3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Anus Neoplasms
2
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Intraepithelial Lesions
1
Sleep Apnea, Obstructive
1
Sarcoma
1
Rectal Neoplasms
1
Precancerous Conditions
1
Polycythemia Vera
1
Pneumonia
1
Pancreatic Neoplasms
1
Pain
1
Osteoporosis
1
Oropharyngeal Neoplasms
1
Obesity
1
Mouth Neoplasms
1
Lung Diseases, Interstitial
1
Leukemia, B-Cell
1
Hypertension
1
Hypercholesterolemia
1
Homosexuality
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Interventions
ofatumumab
3
Vincristine
2
Rituximab
2
Lenalidomide
2
Bortezomib
2
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
nelarabine
1
immunotoxin HA22
1
fludarabine
1
bempegaldesleukin
1
Whole-Body Irradiation
1
Tablets
1
Panobinostat
1
Observation
1
Nivolumab
1
Mitoxantrone
1
Methotrexate
1
Mercaptopurine
1
Everolimus
1
Etoposide
1
Drug Therapy
1
Dexamethasone
1
DTRMWXHS-12
1
Cytarabine
1
Cyclophosphamide
1
Clofarabine
1
Cladribine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, B-Cell
×
Observation
×
Clear all
NCT01039376
2019-07-30
PROLONG
Novartis
Phase 3
Terminated
480 enrolled
30 charts